Merit Medical Systemsの空売り状況は、投資家がMerit Medical Systemsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Merit Medical Systems (NASDAQ:MMSI) 株価情報, 空売り情報

Merit Medical Systems

Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.

Analyst Ratings

MMSI

Merit Medical Systems (NASDAQ:MMSI) はこの3カ月間で11人のアナリストに分析され、ベアリッシュからブルリッシュまで多岐にわたる視点が明らかになりました。

アナリストの分析｜メリットメディカルシステムに関係する11の意見

Merit Medical Systems, Inc. - Common Stock

Merit Medical Systems Inc

Merit Medical Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) is <a href="https://www.benzinga.com/pressreleases/25/04/g44675330/merit-medical-systems-to-announce-first-quarter-2025-results-on-april-24-2025" target="_blank" rel="noreferrer noopener">scheduled to release</a> its first quarter 2025 adjusted EPS of 75 cents and sales of $352.82 million, as per <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">data on Benzinga Pro</a>.
Merit develops, manufactures and distributes proprietary medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy.
Barrington Research writes that in 2024, about 41% of Merit Medical&#8217;s revenue of $1.36 billion was generated outside of the U.S., and about 11% of Merit Medical&#8217;s 2024 revenue <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43956487/merit-medical-reports-fourth-quarter-and-full-year-2024-results-and-issues-fiscal-year-2025-guidan" rel="noreferrer noopener">was generated in China</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/44763932/stellantis-q1-shipments-decline-9-but-gains-in-south-america-and-eu-offer-relief" rel="noreferrer noopener">Stellantis Q1 Shipments Decline 9%, but Gains in South America and EU Offer Relief</a>
Analyst Michael Petusky also highlights the company&#8217;s several manufacturing and packaging facilities outside of the U.S., including in Mexico, Brazil, Ireland, France, The Netherlands and Singapore — along with U.S.-based manufacturing and packaging in Utah, Texas, Virginia and Minnesota.
Petusky believes most of the products Merit makes in Mexico — its most important international facility — are protected by the USMCA trade agreement, which is still in effect. Thus, the company is shielded from recent U.S. <a href="https://www.benzinga.com/topic/tariffs">tariffs on Mexican goods</a>.
The analyst maintains the outperform rating and <a target="_blank" href="https://www.benzinga.com/quote/MMSI/analyst-ratings" rel="noreferrer noopener">price target of $111</a>.
But the growing trade tensions between the U.S. and China pose a serious risk to Merit&#8217;s $150 million revenue from China.
While it seems unlikely that tariffs over 100% will last long between the world&#8217;s two biggest economies, if they do, it would significantly affect Merit&#8217;s financial outlook for the rest of 2025 and beyond, including its long-term growth plans.
Merit Medical forecasts fiscal year 2025 revenue of $1.47 billion-$1.49 billion versus a consensus of $1.477 billion. The company estimates Adjusted EPS of $3.58-$3.70 versus the consensus of $3.74.
Continued Growth Initiatives covers the 2024-2026 timeframe, and key goals include 5%-7% annual organic revenue growth, $400 million in aggregate free cash flow, and a minimum of 200 bps points of adjusted operating margin improvement to at least 20% by the end of the long-range plan.
MMSI Price Action: Merit Medical Systems stock is up 0.16% at $91.69 at publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44762037/morgan-stanleys-q1-equity-revenue-jumps-45-buoyed-by-asian-clients-amid-volatile-trading-environment" target="_blank" rel="noreferrer noopener">Morgan Stanley Q1 Credit Loss Provision Jumps To $135 Million On &#8216;Weakening Macroeconomic Forecast,&#8217; Equity Revenue Jumps 45%</a></li>
</ul>
Photo: New Africa via Shutterstock

Analyst Color

Earnings

News

Guidance

Health Care

Previews

General

US-China Trade Tensions Pose Risk To Merit Medical's $150 Million Revenue From China

Barrington Research analyst Michael Petusky maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Outperform and maintains $111 price target.

Price Target

Barrington Research Maintains Outperform on Merit Medical Systems, Maintains $111 Price Target

Needham analyst Mike Matson reiterates Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and maintains $116 price target.

Reiteration

Needham Reiterates Buy on Merit Medical Systems, Maintains $116 Price Target

Merit Medical Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NYSE">MMSI</a>) short percent of float has risen 7.66% since its last report. The company recently reported that it has 3.24 million shares sold short, which is 8.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.63 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Merit Medical Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743601521_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Merit Medical Systems has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Merit Medical Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Merit Medical Systems's peer group average for short interest as a percentage of float is 7.78%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Do Investors Really Feel About Merit Medical Systems?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keefe, Bruyette &amp; Woods analyst Ryan Tomasello initiated coverage on Zillow Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) with a Market Perform rating and announced a price target of $80. Zillow shares closed at $70.35 on Thursday. <a href="https://www.benzinga.com/quote/Z/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Andrew Cooper initiated coverage on UFP Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFPT#NASDAQ">UFPT</a>) with a Market Perform rating. UFP Technologies shares closed at $110.09 on Thursday. <a href="https://www.benzinga.com/quote/UFPI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Andrew Cooper initiated coverage on Integer Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITGR#NYSE">ITGR</a>) with an Outperform rating and announced a price target of $145. Integer shares closed at $117.50 on Thursday. <a href="https://www.benzinga.com/quote/ITGR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Robbie Marcus initiated coverage on Merit Medical Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with an Overweight rating and announced a price target of $120. Merit Medical shares closed at $103.27 on Thursday. <a href="https://www.benzinga.com/quote/MMSI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Michael Goldsmith initiated coverage on Getty Realty Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTY#NYSE">GTY</a>) with a Neutral rating and announced a price target of $32. Getty Realty shares closed at $30.57 on Thursday. &nbsp;<a href="https://www.benzinga.com/quote/GTY/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MMSI stock? Here&#8217;s what analysts think: 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock">Jim Cramer: Stryker Is A &#8216;Good&#8217; Company, Says He Likes This Utilities Stock</a></li>
</ul>
Photo: Shutterstock

Initiation

Pre-Market Outlook

Markets

ITGR

UFPT

This Merit Medical Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

In the last three months, 12 analysts have published ratings on Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Merit Medical Systems and provided 12-month price targets. The average target is $117.08, accompanied by a high estimate of $128.00 and a low estimate of $109.00. This current average reflects an increase of 1.17% from the previous average price target of $115.73. 
<img src="https://www.benzinga.com/files/images/story/2025/1743163293_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Merit Medical Systems is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$120.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$111.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$127.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$117.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$116.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$128.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$122.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$114.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$109.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Merit Medical Systems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merit Medical Systems compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Merit Medical Systems's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Merit Medical Systems's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MMSI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Merit Medical Systems analyst ratings.</a>
<h2>Delving into Merit Medical Systems's Background</h2>
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
<h3>Financial Milestones: Merit Medical Systems's Journey</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Merit Medical Systems showcased positive performance, achieving a revenue growth rate of 9.44% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.87%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Merit Medical Systems's ROE excels beyond industry benchmarks, reaching 2.07%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.17%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.58.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Merit Medical Systems: Insights From 12 Financial Analysts

JP Morgan analyst Robbie Marcus initiates coverage on Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Overweight rating and announces Price Target of $120.

JP Morgan Initiates Coverage On Merit Medical Systems with Overweight Rating, Announces Price Target of $120

Biotech

Merit Medical Enrolls First Patient In PREEMIE Study

Disclosed on March 6, FRED LAMPROPOULOS, President and CEO at Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), executed a substantial insider sell as per the latest SEC filing.
What Happened: LAMPROPOULOS's decision to sell 34,319 shares of Merit Medical Systems was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000856982/000141588925007272//Archives/edgar/data/856982/000141588925007272/0001415889-25-007272-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The total value of the sale is $3,564,069.
In the Friday's morning session, Merit Medical Systems's shares are currently trading at $101.45, experiencing a down of 0.28%.
<h3>About Merit Medical Systems</h3>
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
<h3>Merit Medical Systems: A Financial Overview</h3>
Revenue Growth: Merit Medical Systems displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 9.44%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 48.71%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Merit Medical Systems exhibits below-average bottom-line performance with a current EPS of 0.48.
</li>
</ul>
Debt Management: Merit Medical Systems's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.58.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 50.11, Merit Medical Systems's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 4.45 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio of 21.64, the company's market valuation exceeds industry averages.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000856982">Check Out The Full List Of Merit Medical Systems's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Selling: FRED LAMPROPOULOS Unloads $3.56M Of Merit Medical Systems Stock

Disclosed in a recent SEC filing on March 6, Lloyd, Chief Legal Officer at Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), made a noteworthy transaction involving the exercise of company stock options.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000856982/000141588925007268//Archives/edgar/data/856982/000141588925007268/0001415889-25-007268-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that Lloyd, Chief Legal Officer at Merit Medical Systems, a company in the Health Care sector, just exercised stock options worth 30,000 shares of MMSI stock with an exercise price of $55.73.
The Friday morning market activity shows Merit Medical Systems shares down by 0.28%, trading at $101.45. This implies a total value of $1,371,600 for Lloyd's 30,000 shares.
<h3>About Merit Medical Systems</h3>
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
<h3>Key Indicators: Merit Medical Systems's Financial Health</h3>
Positive Revenue Trend: Examining Merit Medical Systems's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 9.44% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 48.71%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): Merit Medical Systems's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.48.
</li>
</ul>
Debt Management: Merit Medical Systems's debt-to-equity ratio is below the industry average at 0.58, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: Merit Medical Systems's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 50.11.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 4.45 is above industry norms, reflecting an elevated valuation for Merit Medical Systems's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 21.64 positions the company as being more valued compared to industry benchmarks.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Breaking Down the Significance of Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000856982">Check Out The Full List Of Merit Medical Systems's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Strategic Sale: Brian G Lloyd Decides To Exercise Options Worth $1.37M At Merit Medical Systems

Barrington Research analyst Michael Petusky maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Outperform and lowers the price target from $115 to $111.

Barrington Research Maintains Outperform on Merit Medical Systems, Lowers Price Target to $111

Analysts' ratings for Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) over the last quarter vary from bullish to bearish, as provided by 13 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $118.08, with a high estimate of $128.00 and a low estimate of $109.00. Observing a 2.34% increase, the current average has risen from the previous average price target of $115.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1740596467_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Merit Medical Systems is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$127.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$117.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$116.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$128.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$122.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$114.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$109.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$114.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$125.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Merit Medical Systems. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merit Medical Systems compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Merit Medical Systems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Merit Medical Systems's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MMSI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Merit Medical Systems analyst ratings.</a>
<h2>Delving into Merit Medical Systems's Background</h2>
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for use in interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment. The United States generates the majority of the revenue.
<h3>Key Indicators: Merit Medical Systems's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Merit Medical Systems's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.81% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 8.37%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Merit Medical Systems's ROE excels beyond industry benchmarks, reaching 2.18%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Merit Medical Systems's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.2%, the company showcases efficient use of assets and strong financial health.
Debt Management: Merit Medical Systems's debt-to-equity ratio is below the industry average at 0.62, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Merit Medical Systems Stock: A Deep Dive Into Analyst Perspectives (13 Ratings)

Canaccord Genuity analyst Jon Young maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and lowers the price target from $128 to $127.

Canaccord Genuity Maintains Buy on Merit Medical Systems, Lowers Price Target to $127

Wells Fargo analyst Larry Biegelsen maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Overweight and lowers the price target from $120 to $117.

Wells Fargo Maintains Overweight on Merit Medical Systems, Lowers Price Target to $117

Needham analyst Mike Matson maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and lowers the price target from $122 to $116.

Needham Maintains Buy on Merit Medical Systems, Lowers Price Target to $116

Merit Medical Sees FY25 Revenue $1.47B-$1.49B Vs $1.477B Estimate; Sees FY25 Adj. EPS $3.58-$3.70 Vs $3.74 Estimate

Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) reported quarterly earnings of $0.93 per share which beat the analyst consensus estimate of $0.83 by 12.05 percent. This is a 14.81 percent increase over earnings of $0.81 per share from the same period last year. The company reported quarterly sales of $355.20 million which beat the analyst consensus estimate of $351.35 million by 1.10 percent. This is a 9.46 percent increase over sales of $324.51 million the same period last year.

Earnings Beats

Merit Medical Systems Q4 2024 Adj EPS $0.93 Beats $0.83 Estimate, Sales $355.20M Beat $351.35M Estimate

AHCO

ALLT

ARQT

AXGN

AXON

BASE

BGFV

BLZE

BTDR

BWIN

CART

CAVA

CBLL

CCCS

CECO

CGBD

CHRD

CIFR

CPNG

CPSS

DAWN

DNUT

DOCN

DRVN

ELAN

EXLS

FIHL

FLYW

FSLR

FULC

GPOR

HRMY

HSIC

HURN

HYLN

IART

ICCC

IGIC

IMOS

INGN

INTU

INVX

IPAR

ITRI

IVAC

JACK

JAZZ

KEYS

KNSA

LCID

LGIH

LIVN

LMND

LXFR

MASI

MATX

MFIC

MIDD

MPLN

MRVI

NOVT

NXRT

Earnings Scheduled For February 25, 2025

Merit Medical Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NYSE">MMSI</a>) short percent of float has risen 10.66% since its last report. The company recently reported that it has 2.94 million shares sold short, which is 7.37% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.27 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Merit Medical Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739385916_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Merit Medical Systems has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Merit Medical Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Merit Medical Systems's peer group average for short interest as a percentage of float is 6.89%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Merit Medical Systems's Recent Short Interest

Piper Sandler analyst Jason Bednar reiterates Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Overweight and raises the price target from $114 to $116.

Piper Sandler Reiterates Overweight on Merit Medical Systems, Raises Price Target to $116

Press Releases

Merit Medical Announces Resignation of President, Joseph Wright

Merit Medical Announces FDA Approval of the WRAPSODY Cell-Impermeable Endoprosthesis

Merit Medical Announces Preliminary Unaudited Revenue for the Year Ended December 31, 2024 and Plans to Announce Fourth Quarter and Year End 2024 Results and Issue Fiscal Year 2025 Guidance on February 25, 2025

Merit Medical Reports Fourth Quarter and Full Year 2024 Results and Issues Fiscal Year 2025 Guidance

First Patient Enrolled in Merit Medical's PREEMIE Study

Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership

Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)

Updated ASGE Clinical Practice Guideline Includes TIF 2.0 and cTIF for Management of GERD

Comments

Merit Medical Systems

空売り

Merit Medical Systems (NASDAQ:MMSI) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル